Navigation Links
Appeal Court's Direction on Claim Construction Is Strategically Important for Butamax's Case Against Gevo Scheduled for April 2013

WILMINGTON, Del., Nov. 19, 2012 /PRNewswire/ -- Butamax™ Advanced Biofuels, LLC, the leading biobutanol technology company, commented on the decision by the Federal Circuit.  While the Federal Circuit affirmed the District Court's preliminary injunction decision, Butamax is pleased with the Federal Circuit's direction on claim construction.  The District Court's narrow interpretation of Butamax's patent was not endorsed and, in the words of the Federal Circuit:

(Logo: )

"…this court's affirmance should not be read to endorse the trial court's very questionable construction of the claim term "acetohydroxy acid isomeroreductase" – that is "as an enzyme that is solely NADPH dependent.  The trial court should reconsider its construction when it holds a Markman hearing."

Gevo had argued that it did not infringe Butamax's patent because of this narrowed scope of the KARI enzyme.  Butamax is confident that, with a revised claim construction, it will succeed in its infringement arguments against Gevo.  The Federal Circuit also commented that Butamax did not demonstrate that Gevo's arguments on validity lacked substantial merit as required for the grant of a preliminary injunction. Butamax will address these issues at the April 2013 trial, which will also cover the full scope of the '188 and '889 patents.

About Butamax
Butamax™ Advanced Biofuels, LLC was formed to develop and commercialize biobutanol as a next generation renewable biofuel for the transport market. The company benefits from the synergy of DuPont's proven industrial biotechnology experience and BP's global fuels market knowledge. Butamax's proprietary technology offers a cost-advantaged manufacturing process for isobutanol with value from field to pump. For more information, visit

Butamax™ is a trademark of Butamax™ Advanced Biofuels, LLC.

Media Contact:
Pam Schools 910-777-7119


SOURCE Butamax Advanced Biofuels, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. State-of-the-Art Novelda NVA6000 Impulse Radar Transceiver Finds Widespread Appeal and Applications
2. Sequenom, Inc. Files Notice Of Appeal Of Preliminary Injunction Denial
3. PharmaDirections Succeeds Through its Client’s Successes: Cortendo Receives Positive Orphan Drug Opinion from EMA for NormoCort for Cushing’s Disease
4. Why Medicare Carrier Proposes Major Changes in the Handling of Code Stacked Molecular Test Claims is Topic of December 20 Audio Conference
5. Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space
6. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
7. 3M Withdraws Blackmail Claims Against Harvey Boulter From New York Court
8. The Energy Scientific World Acclaims the Global Energy Prize 2012 Laureates
9. Rosetta Genomics Pays Off Secured Loan and Reclaims Unencumbered Rights to All Assets
10. MetaStat, Inc. Announces Allowance of Patent Claims
11. All Market Research New Report @ Polyvinyl Chloride (PVC) Global Market to 2020 - Growth from Asia-Pacific Construction, Packaging and Electrical Sectors Continues to Drive Demand
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015  Northwest Biotherapeutics (NASDAQ: ... developing DCVax® personalized immune therapies for solid tumor cancers, ... an additional independent director, and the Company welcomes ... allegations in a recent anonymous internet report on NW ... initiatives. Linda Powers stated, "We agree ...
(Date:11/27/2015)... PA (PRWEB) , ... November 27, 2015 , ... ... Technical Program that includes over 2,000 technical presentations offered in symposia, oral ... chemistry and applied spectroscopy, covers a wide range of applications such as, but ...
(Date:11/25/2015)...  PharmAthene, Inc. (NYSE MKT: PIP) announced  today that ... plan (Rights Plan) in an effort to preserve the ... Section 382 of the Internal Revenue Code (Code). ... of its NOLs could be substantially limited if the ... 382 of the Code. In general, an ownership change ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... its business and prospects remain fundamentally strong and ... (zoptarelin doxorubicin) recently received DSMB recommendation to continue ... following review of the final interim efficacy and ... Primary Endpoint in men with heavily pretreated castration- ...
Breaking Biology Technology:
(Date:11/17/2015)... , November 17, 2015 ... au 19 novembre  2015.  --> Paris ... --> DERMALOG, le leader de l,innovation biométrique, ... la fois passeports et empreintes sur la même surface ... les passeports et l,autre pour les empreintes digitales. Désormais, ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
Breaking Biology News(10 mins):